Home > Boards > US Listed > Medical - Equipment >

Neovasc, Inc. (NVCN)

Add NVCN Price Alert      Hide Sticky   Hide Intro
Moderator: beambe, 12thman, EnergySaver, PyschoNoobStock, maz1978 , Joecanada13
Search This Board: 
Last Post: 4/26/2018 10:54:56 AM - Followers: 234 - Board type: Free - Posts Today: 14

Trading for
$0.061 as of Thurs. March 29th, 2018, well under two recent Price Targets of $2.00 and $0.50.
Increased chatter amongst investors of a Partnership or Buyout, see below. 

Latest Analyst Ratings:

March 29th, 2018 3:07 AM EDT
Neovasc Inc. PT updated to $2.00 at Leerink Partners, states that 'Tiara Clinical Trials Continue to Progress' Maintains 'Outperform' Rating.

March 29th, 2018 
Canaccord Genuity Updates Neovasc Inc (US) (NVCN) Price Target to $0.50 and has a "Buy" rating.

Latest Earnings Report - March 28th, 2018
EPS of $-0.28 misses by $-0.02 
Revenue of $5.39M (- 43.3% Y/Y) beats by $1.29M

Trader's takeaway from the latest Earnings Report: (Updated on April 1st, 2018)
1. No R/S mentioned, 2. Tiara Prescreen implementation in Europe soon (as early as this week), 3. Updates on Tiara / Reducer enrollments shown to have been very successful and increasing in size, 4. Cash to last through Q3 2018, 5. Revenues were down/but so were expenses.

Also on the conference call, they reported that the $112 M lawsuit has been fully paid and settled. Neovasc said that “there are no other monetary damages arising from the award,” and announced that it will remain the joint inventor of its ‘964 patent related to its Tiara transcatheter mitral valve replacement device. Neovasc will share the patent along with 2 employees of CardiAQ Valve, with both parties “having freedom to use the patent without an obligation to pay royalties to the other", according to a press release. Source: NeoVasc shares surge 45% on affirmed Tiara patent case decision against Edwards.

Possible Partnership in the works?
This was taken from the latest Earnings Conference call on March 28th, 2018 (link to entire transcript provided above, courtesy of
Newly acquired CEO/President Fred Colen hints at being open to a partnership.  Have a look at what he says:
Possible partnership?

Possible Buy Out in the works? 
Check out newly acquired CEO Fred Colen's bio below (spoiler alert: he worked with $BSX for 8 years as CTO) and see how this all ties together. 

Don't Be Surprised if Boston Scientific (BSX) Buys Neovasc (NVCN)- JMP  

MARCH 30, 2018 Article:

Neovasc has a unique opportunity to take a share of that US$16.2 Billion with this patent along with many other patents that they own.
Patent # 

Neovasc's Tiara and other TMVR devices
US$75 MILLION AGREEMENT 12/02/16}}}}

Neovasc and Boston Scientific Reach US$75 Million Agreement 
12/2/2016 7:00:00 AM - PR Newswire 

Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities 
12/2/2016 7:00:00 AM - PR Newswire 

NVCN + BSX = 15% stake = +350% for stock


Fred Colen - President and CEO

Neovasc Inc. (Nasdaq: NVCN), a front-runner in minimally invasive transcatheter mitral valve technologies today announced that its board of directors (the "Board") has appointed Fred A. Colen as president and chief executive officer effective immediately. This leadership transition is a key element of the Company's strategy to support plans for the commercialization of its new-to-market Reducer™ ("Reducer") product in Europe and the advancement of its Tiara™ ("Tiara") mitral valve clinical program. Alexei Marko, Neovasc's outgoing CEO, will maintain his role as a Director on the Neovasc Board of Directors and continue to serve as an advisor to the Company.  

"After ten years building Neovasc, I am convinced that now is the time for new leadership to take the Company to the next level. I am especially pleased that an industry leader of Fred Colen's caliber has accepted this opportunity," said Alexei Marko, outgoing CEO of Neovasc. "I look forward to my continued involvement as a board member." 

Fred Colen has contributed to many significant turnarounds in his career, including the post-acquisition Guidant Company, which became the CRM division of Boston Scientific, a firm with which he held progressively senior executive roles over 11 years, including Chief Technology Officer from 2001-2008 and Member of the Executive Committee from 2001-2010. During his tenure at Boston Scientific, Mr. Colen is credited with numerous successes. As President of the company's Cardiac Rhythm Management (CRM) Group his team regained trust and confidence in the division's implantable pacemakers, leads, defibrillators and re-synchronization devices, increasing annual product revenue growth by over 10% in a flat US market and growing global divisional operating income from below 10% to 25% of sales, exceeding the planned annual free cash flow goals. As Chief Technology Officer, he led the development and global commercial launch for the Company's first- and second-generation implantable drug-eluting coronary stents (the Taxus Express and Taxus Liberte), leading to global market leadership with incremental revenues of US$2 billion annually. The Taxus Express market introduction is viewed as one of the most successful launches ever in the medical device industry. 

Also note:
$BSX Boston Scientific laid off 300 employees just recently on March 27th, 2018
, perhaps to make room for the takeover of $NVCN ?? Who knows?? They already own 15% of NVCN.


                                                                      About Neovasc                                                                        

                                                     Neovasc Inc. is a specialty medical device company that develops, manufactures,
                                                     and markets products for the rapidly growing cardiovascular marketplace.

                                                                        Our products include the Tiara™ technology in development for the transcatheter
                                                                        treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of
                                                                        refractory angina.

                                                                         A Canadian Biotech company, headquartered in Vancouver, B.C. Canada, we are a
                                                                         publicly traded company, listed on NASDAQ: (NVCN) and the Toronto Stock
                                                                         Exchange TSX: (NVC) 




                                                    BUYOUT POTENTIAL                                        
              ------------------>>>>>>>>>>>>>Recent deals involving mitral valve companies<<<<<<<<<<<<<<--------------
"Great info and a MUST READ on the demand and for acquisitions for these type of companies here from last year this month now that remainder or any legal issues are getting ironed out through the final appeals days now , EVEN SHOWS THE $$ VALUES OF THE BOUGHT COMPANIES TOO:"


Concensus Recommendation courtesy of 
Updated: April 1st, 2018:   STRONG BUY.

STRONG BUY                                  
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NVCN News: Report of Foreign Issuer (6-k) 04/11/2018 04:45:00 PM
NVCN News: Neovasc Announces Receipt of US$7.1 Million from Exercise of Series C Warrants 04/11/2018 04:30:00 PM
NVCN News: Neovasc Announces Receipt of US$7.1 Million from Exercise of Series C Warrants 04/11/2018 04:30:00 PM
NVCN News: Neovasc Announces Receipt of US$7.1 Million from Exercise of Series C Warrants 04/11/2018 04:30:00 PM
NVCN News: Neovasc Announces Receipt of US$7.1 Million from Exercise of Series C Warrants 04/11/2018 04:30:00 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#5470  Sticky Note Rumous circulating that Boston Scientific $BSX may still EnergySaver 03/31/18 01:39:43 PM
#4414  Sticky Note Cliff note DD packet for those new to maz1978 03/10/18 10:12:07 AM
#8130   We are range bound between .033 and .065 petergeorge 04/26/18 10:54:56 AM
#8129   .0430 todays bottom We need a nice bounce petergeorge 04/26/18 10:41:11 AM
#8128   NVCN broke support, down we go! mario3349 04/26/18 10:39:08 AM
#8127   It should take that long for the 14/50 petergeorge 04/26/18 10:30:44 AM
#8126   Could you explain why 10-15 days? LiveLife 04/26/18 10:22:03 AM
#8125   we have about another 10-15 days before breakout petergeorge 04/26/18 09:50:37 AM
#8124   Looks like bottom forming. Time to buy LiveLife 04/26/18 09:50:21 AM
#8123   I agree.NVCN $$$$$ SOON OR LATE toro bravo 04/26/18 09:45:21 AM
#8122   The ultimate day silence, zero people fluffing stuff leegy1984 04/26/18 09:44:52 AM
#8121   Just gonna keep adding here, the people that Runners123 04/26/18 09:41:53 AM
#8120   Easy mr cow....take a breather and relax my FUDUDE 04/26/18 07:44:46 AM
#8119   Just hold on lets first make it thorough cash_cow1 04/26/18 07:41:31 AM
#8118   Your logic & your DD is really off leegy1984 04/26/18 07:40:15 AM
#8117   Volume id getting less and less while the leegy1984 04/26/18 07:33:12 AM
#8116   Sounds good to me.Lets get wealthy. buypumps 04/25/18 09:55:05 PM
#8115   Neovasc NVCN will be trading .25 within a mikeotc 04/25/18 09:41:43 PM
#8114   Who's we.My stop loss start to trigger from buypumps 04/25/18 09:04:02 PM
#8113   Going to 0 in 2019 Nirvana1 04/25/18 08:37:57 PM
#8112   If .04 doesn’t hold, we are going to Nirvana1 04/25/18 08:29:25 PM
#8111   Nvcn holding up well considering major dilution.Was reading buypumps 04/25/18 05:43:23 PM
#8110   * * $NVCN Video Chart 04-25-18 * * ClayTrader 04/25/18 04:05:28 PM
#8109   An Eye on Data – Neovasc Inc (NASDAQ: NVCN) NYK PT 04/25/18 03:44:44 PM
#8108   Mr diluter kicking some shares to the curb buypumps 04/25/18 03:19:50 PM
#8107   Until the large block "sells" get off the mario3349 04/25/18 03:13:58 PM
#8106   NO R/S NO OTC UNTIL SEPTEMBER toro bravo 04/25/18 02:37:54 PM
#8105   MACD Crossover. Runs Very Soon !! George1234 04/25/18 01:49:46 PM
#8104   Risks Reverse split and shorts hammer it down buypumps 04/25/18 01:45:55 PM
#8103   Q1 earnings are expected to be announced on George1234 04/25/18 01:35:48 PM
#8102   Big casino Is dare today up 100 or akamaii 04/25/18 11:20:59 AM
#8101   Why is risk here? toro bravo 04/25/18 11:02:09 AM
#8100   Mr dilute still unloading 500 k asks.PPS holding buypumps 04/25/18 10:59:56 AM
#8099   Really low volume pm. Hope that's a good sign. Wantcash 04/25/18 09:18:08 AM
#8098   So the rsi is over bought what’s the akamaii 04/25/18 08:39:08 AM
#8096   Ya mean move to da left, don't ya??? Don 04/25/18 07:41:04 AM
#8095   Like I said, I aint selling at all. leegy1984 04/25/18 06:25:33 AM
#8094   You’re up Early let’s see what she does akamaii 04/25/18 06:11:44 AM
#8092   Neovasc, Inc $NVCN has 34 institutional investors and NYK PT 04/25/18 05:15:42 AM
#8091   No, that's too low! Move the decimal one InvestGibbon 04/25/18 12:17:54 AM
#8090   Not all are in favor. Lots of shorts. Lots Hazmat927d 04/24/18 11:23:03 PM
#8089   36000 NVCN watchers on stocktwits.We all cannot be buypumps 04/24/18 10:18:57 PM
#8088   This is a no brainer.. only going up Eric83 04/24/18 09:05:03 PM
#8087   Long term potential pps rise.Much greater than lower buypumps 04/24/18 07:42:54 PM
#8086   Arnold did a valve replacement. Market cap 45m akamaii 04/24/18 07:11:47 PM
#8085   tic tac tic tac.... toro bravo 04/24/18 07:02:51 PM
#8084   Like most stocks this will open soon take akamaii 04/24/18 04:32:23 PM
#8083   S.S this still a buy? don estaban 04/24/18 04:27:08 PM
#8082   * * $NVCN Video Chart 04-24-18 * * ClayTrader 04/24/18 04:07:38 PM
#8081   beambe buy beambe 04/24/18 03:52:20 PM
#8080   I agree, I have made nice money shorting mario3349 04/24/18 03:12:14 PM
#8079   I’m hoping to make money here, but grasping Hazmat927d 04/24/18 03:04:16 PM